Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia

Blood

Volumn 111, Issue 4, 2008, Pages 2382-2384

  Oki, Yasuhiro ^a   Jelinek, Jaroslav ^a   Shen, Lanlan ^a   Kantarjian, Hagop M ^a   Issa, Jean Pierre J ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; JANUS KINASE 2;

ADULT; AGED; ALLELE; ARTICLE; CANCER REGRESSION; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA METHYLATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENE MUTATION; HUMAN; MALE; PRIORITY JOURNAL; PYROSEQUENCING; RANDOMIZED CONTROLLED TRIAL;

EID: 41349083325     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-07-103960     Document Type: Article

References (8)

1. Kantarjian H, Issa JP, Rosenfeld CS, et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106:1794-1803.
2. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of three schedules of low-dose decitabine in higher risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood. 2007;109:52-57.
3. Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′- deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol. 2000;18:956-962.
4. Jelinek J, Oki Y, Gharibyan V, et al. JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosomenegative CML, and megakaryocytic leukemia. Blood. 2005;106:3370-3373.
5. Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Mutations and promoter methylation status of NPM1 in myeloproliferative disorders. Haematologica. 2006;91:1147-1148.
6. Shen L, Kantarjian H, Saba H, et al. CpG island methylation is a poor prognostic factors in myelodysplastic syndrome patients and is reversed by decitabine therapy: results of a phase III randomized study [abstract]. Blood. 2005;106:233a
7. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal pyrosequencing methylation analysis of CpG sites. Biotechniques. 2003;35:146-150.
8. Sigalotti L, Altomonte M, Colizzi F, et al. 5-Aza-2′-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood. 2003;101:4644-4646.